Described are stable liquid formulations of nitrogen mustards. The nitrogen mustard includes mechlorethamine, cyclophosphamide, ifosfamide, melphalan, chlorambucil, uramustine, thiotepa and combinations thereof. The formulation includes a non-aqueous liquid having at least a first solvent either individually or in combination with one or more additional solvents. The formulation further includes an antioxidant, an organic acid, and a source of chloride ions.

589373 Disclosed is the use of cannabinoid tetrahydrocannabinol (THC) in the form of a cannabis plant extract in combination with a non-cannabinoid chemotherapeutic agent selected from the group consisting of: an alkylating agent (such as alkyl sulfonates, busulfan, ethyleneimines, methylmelamines, hexamethymelamine, altretamine, thiotepa, nitrogen mustards, cyclophosphamide, mechlorethamine, mustine, uramustine, uracil mustard, melphalan, chlorambucil, ifosfamide, nitrosureas, carmustine, cispl...

The present invention relates to a composition and functional health food including nicotinamide for preventing or treating alkylating agent-induced apoptotic neurodegeneration, to a method for preventing or treating alkylating agent-induced apoptotic neurodegeneration by administering nicotinamide or a composition including nicotinamide, and to the use of nicotinamide for producing drugs for preventing or treating alkylating agent-induced apoptotic neurodegeneration. According to the present in...

Combinations of (a) taxol taxotere or their derivatives with (b) a therapeutic substance are used in the treatment of neoplastic disorders.Pref. (b) is an alkylating agent (esp. cyclophosphamide ifosamide melphalan hexamethyl melamine thiotepa and dacarbazine) an anti-metabolite (esp. 5-fluorouracil cytarabin methotrexate idatrexate and trimetrexate) a fusel poison (esp. a vinca alkaloid their synthetic and semi-synthetic analogues estramustine and taxoids) an epidophyllotoxin (esp. etoposide or...

The invention relates to compositions containing nanoparticles and to uses o f said compositions for encapsulating therapeutically active substances in cel ls by means of nanoparticles with a particular coating. The particles are chemically formed in such a way as to enable a high intracellular absorption into the cells. The encapsulation requires no direct binding between nanoparticles and the therapeutically active substance. The encapsulation enables an increased efficiency of the substance w...

PURPOSE: To obtain a stable lyophilized composition of thiotepa which is an antitumor alkylating agent by preparing an aqueous solution of the thiotepa adding a base to the resultant aqueous solution regulating the pH to a weakly alkaline one and freeze-drying the regulated aqueous solution.CONSTITUTION: This lyophilized composition for parenteral administration is obtained by preparing an aqueous solution of thiotepa represented by the formula i.e. 11'1"-phosphinothioylidynetrisaziridine then a...

Combinations of taxane deriv and antineoplastic agent Combinations of (a) taxol taxotere or their derivatives with (b) a therapeutic substance are used in the treatment of neoplastic disorders. Pref. (b) is an alkylating agent (esp. cyclophosphamide ifosamide melphalan hexamethyl melamine thiotepa and dacarbazine) an anti-metabolite (esp. 5-fluorouracil cytarabin methotrexate idatrexate and trimetrexate) a fusel poison (esp. a vinca alkaloid their synthetic and semi-synthetic analogues estramust...